Urinary Disorders

Last updated 1 Jun 2026 · Urology / Nephrology

📋 Key Information Summary

📋

Dysuria in an otherwise well, non-pregnant adult is most commonly caused by lower urinary tract infection (UTI); a dipstick midstream urine (MSU) is usually sufficient for diagnosis in uncomplicated cases.
Use the Dysuria–Pyuria–Nitrite triad to guide empirical antibiotic initiation: pyuria + nitrite positivity has >90% positive predictive value for bacterial cystitis in women aged 16–65.
Haematuria must never be attributed to UTI alone until serious underlying causes are excluded — all patients with visible (macroscopic) haematuria and those ≥40 years with persistent non-visible haematuria require urgent urological assessment.
Red flags requiring urgent referral: painless visible haematuria, age >40 with persistent microscopic haematuria, clot retention, palpable mass, unexplained weight loss, or constitutional symptoms.
Bladder cancer is the 9th most common cancer in Australia; smoking is the strongest modifiable risk factor. CT urogram + cystoscopy form the backbone of investigation.
Nephritic syndrome is defined by haematuria (dysmorphic RBCs/casts), hypertension, oedema, and acute kidney injury — think glomerulonephritis until proven otherwise.
IgA nephropathy is the most common primary glomerulonephritis worldwide and in Australia; presents with episodic macroscopic haematuria concurrent with upper respiratory or gastrointestinal infections.
Post-streptococcal glomerulonephritis (PSGN) remains prevalent in Aboriginal and Torres Strait Islander communities, particularly in remote Northern Territory and Central Australia — sore throat or impetigo 1–3 weeks preceding onset is the classic history.
Kidney biopsy is required to confirm IgA nephropathy; PSGN can often be diagnosed clinically with serology (low C3, elevated anti-streptolysin O / anti-DNase B) and may not require biopsy.
ACE inhibitors or ARBs are first-line renoprotective therapy in proteinuric glomerulonephritis; corticosteroids are reserved for progressive IgA nephropathy with persistent proteinuria >1 g/day despite maximal supportive care.
All patients with glomerulonephritis require monitoring of eGFR, urine ACR, blood pressure, and serum albumin — refer to nephrology when eGFR is declining or proteinuria exceeds 0.5 g/day.
Aboriginal and Torres Strait Islander Australians experience disproportionately high rates of kidney disease; culturally safe care, point-of-care testing in remote communities, and chronic disease management through Aboriginal Community Controlled Health Organisations are essential.

Introduction & Australian Epidemiology

Urinary symptoms — including dysuria, haematuria, frequency, urgency, and loin pain — are among the most common presentations in Australian primary care, emergency departments, and urology clinics. A systematic diagnostic approach is essential because the differential spans benign self-limiting conditions (e.g., uncomplicated cystitis) through to life-threatening malignancies (e.g., bladder cancer) and progressive autoimmune renal diseases (e.g., IgA nephropathy, post-streptococcal glomerulonephritis).

In Australia, urinary tract infections account for approximately 2.5 million general practice consultations annually. Bladder cancer affects around 3,100 Australians each year, with a male-to-female ratio of approximately 3:1 and a median age at diagnosis of 73 years. Chronic kidney disease (CKD) affects over 1.7 million Australians, and glomerulonephritis accounts for approximately 10–15% of incident end-stage kidney disease (ESKD). Aboriginal and Torres Strait Islander Australians are 3.8 times more likely to be hospitalised with CKD and have ESKD rates 6–8 times higher than non-Indigenous Australians, driven partly by post-infectious glomerulonephritis and rheumatic fever–related renal disease.

This guideline provides a structured diagnostic framework for urinary disorders, covering the assessment of dysuria, the investigation of haematuria, the recognition and management of bladder cancer and nephritic syndrome, and the differentiation of IgA nephropathy from post-streptococcal glomerulonephritis — all within the Australian healthcare context.

⚠️

Never assume haematuria is "just a UTI." While urinary tract infection is the most common cause of dysuria with haematuria in young women, persistent or recurrent haematuria warrants full urological and/or nephrological workup regardless of age.

Dysuria Diagnostic Model

Dysuria (pain or burning on micturition) is a hallmark of lower urinary tract pathology. A structured diagnostic model helps the clinician differentiate infection from non-infectious aetiologies and guides appropriate investigation and treatment.

Differential Diagnosis of Dysuria

Category	Condition	Key Distinguishing Features
Infectious	Uncomplicated cystitis	Dysuria, frequency, urgency; pyuria on dipstick; nitrite +ve; systemically well
Infectious	Complicated UTI / pyelonephritis	Flank pain, fever >38°C, rigors, nausea/vomiting; CVA tenderness
Infectious	Urethritis (STI)	Urethral discharge, sexual contact risk; Chlamydia trachomatis, Neisseria gonorrhoeae
Infectious	Vulvovaginitis	Vaginal discharge, pruritus; Candida, bacterial vaginosis
Non-infectious	Interstitial cystitis / bladder pain syndrome	Chronic pelvic pain >6 weeks; sterile urine; frequency–urgency syndrome
Non-infectious	Urolithiasis	Colicky flank-to-groin pain, microscopic haematuria; may cause dysuria if stone at VUJ
Non-infectious	Prostatitis (acute/chronic)	Perineal pain, obstructive symptoms, tender prostate on DRE
Non-infectious	Urethral stricture / BPH	Weak stream, hesitancy, post-void dribbling; history of instrumentation
Neoplastic	Bladder cancer	Painless visible haematuria; smoking history; age >40

Stepwise Diagnostic Approach

History

Characterise onset, duration, associated symptoms (fever, discharge, haematuria, loin pain), sexual history, past urological history, medications, smoking status, and risk factors for malignancy.

Examination

Vital signs, abdominal examination (suprapubic tenderness, renal CVA tenderness), external genitalia, DRE if indicated (prostate assessment in males), and vaginal examination if STI or vulvovaginitis suspected.

Dipstick Urinalysis

Leucocyte esterase, nitrite, blood, protein, glucose. A positive nitrite + leucocyte esterase in a symptomatic woman is >90% predictive of UTI. A negative nitrite does not exclude UTI (gram-positive organisms do not reduce nitrate).

MSU for Culture

Send for culture and sensitivity in complicated UTI, recurrent UTI, treatment failure, pregnancy, catheter-associated, or when systemic features are present. Uncomplicated cystitis in young women may be treated empirically without culture.

STI Screen

If urethritis, cervicitis, or sexual risk factors are identified: NAAT for C. trachomatis, N. gonorrhoeae, and first-void urine or urethral swab. Consider Mycoplasma genitalium if persistent non-gonococcal urethritis.

Imaging & Referral

Renal tract ultrasound for recurrent UTI, suspected obstruction, or haematuria. CT KUB for suspected urolithiasis. Urgent urology referral for suspected malignancy. Nephrology referral for persistent proteinuria or abnormal renal function.

Empirical Treatment of Uncomplicated Cystitis

💊

Nitrofurantoin

Macrobid® · Macrodantin® · Nitrofurantoin · Antibiotic

Adult dose 100 mg PO BD with food for 5 days

Paediatric dose ≥3 months: 750 mcg/kg PO QID for 5–7 days

Renal adjustment Contraindicated if eGFR <30 mL/min (ineffective and risk of peripheral neuropathy)

PBS status ✔ PBS General Benefit

💊

Trimethoprim

Alprim® · Trimethoprim · Antibiotic

Adult dose 300 mg PO nocte for 3 days (or 150 mg BD)

Paediatric dose ≥1 month: 4 mg/kg (max 300 mg) PO daily for 3–5 days

Renal adjustment Reduce dose if eGFR <30 mL/min; avoid if eGFR <15 mL/min

PBS status ✔ PBS General Benefit

⚠️

Rising resistance: E. coli resistance to trimethoprim exceeds 25% in many Australian regions. Nitrofurantoin remains first-line per Therapeutic Guidelines (eTG). Local antibiograms should guide prescribing. Reserve fluoroquinolones (ciprofloxacin, norfloxacin) for situations where first-line agents are contraindicated or resistant.

Haematuria: Causes, Red Flags & Investigation

Haematuria — the presence of blood in the urine — is a common finding that may be incidental or a sign of serious underlying pathology. It is classified as visible (macroscopic/gross), where blood is seen with the naked eye, or non-visible (microscopic), detected on dipstick or microscopy (≥10 RBCs per high-power field on spun urine).

Aetiology of Haematuria

Source	Glomerular	Urological (Non-Glomerular)
Character	Dysmorphic RBCs, RBC casts, proteinuria predominant	Isomorphic RBCs, clots possible, may be painless
Common causes	IgA nephropathy, PSGN, lupus nephritis, thin membrane disease, Alport syndrome	UTI, urolithiasis, bladder/renal cell carcinoma, BPH, trauma, polycystic kidney disease
Key tests	Urine ACR/PCR, serum complement (C3/C4), ANA, anti-GBM, ANCA, kidney biopsy	CT urogram, cystoscopy, urine cytology, renal tract ultrasound

Red Flags Requiring Urgent Referral

🚨

Painless visible haematuria — most concerning presentation for urothelial malignancy
Age >40 years with persistent non-visible haematuria (≥2 positive dipsticks over 2 weeks) after exclusion of UTI
Visible haematuria with clot retention — requires emergency catheter and bladder washout
Palpable abdominal or flank mass
Constitutional symptoms: unexplained weight loss, night sweats, bone pain
Acute kidney injury (rising creatinine, oliguria) with haematuria — think rapidly progressive glomerulonephritis (RPGN)
Anticoagulant or antiplatelet use — do not dismiss haematuria as drug-related without full investigation

Investigation Pathway

Confirm True Haematuria

Repeat dipstick after 2 weeks. Exclude false positives (menstruation, myoglobinuria, beetroot ingestion). Confirm with urine microscopy for dysmorphic vs isomorphic RBCs and RBC casts.

Assess for Glomerular vs Urological Source

Urine ACR — proteinuria >30 mg/mmol with dysmorphic RBCs and RBC casts suggests glomerulonephritis. Isomorphic RBCs with minimal proteinuria suggest urological cause. Serum creatinine, eGFR, C3, C4.

Urological Pathway

CT urogram (with and without contrast) is the gold-standard imaging for upper tract evaluation. Cystoscopy is mandatory for all patients >40 with visible haematuria and those >60 with persistent non-visible haematuria. Urine cytology has low sensitivity for low-grade tumours but high sensitivity for carcinoma in situ.

Glomerular Pathway

Serology: ANA, anti-dsDNA, ANCA (MPO, PR3), anti-GBM, complement (C3, C4), ASOT, anti-DNase B, serum IgA, hepatitis B & C serology. Urine for red cell morphology and casts. Refer nephrology — kidney biopsy indicated for persistent proteinuria >0.5 g/day, declining eGFR, or systemic features.

Key Investigations for Haematuria

Essential MSU — microscopy, culture, sensitivity Exclude UTI as cause. Urine cytology if malignancy suspected. Available in all Australian pathology labs.

Essential Urine ACR / PCR Quantify proteinuria. ACR ≥30 mg/mol requires nephrology review. MBS item 66892.

Essential Serum creatinine, eGFR, electrolytes, FBC, LFTs Assess renal function. MBS item 66503.

Available Renal tract ultrasound First-line imaging for suspected urolithiasis, hydronephrosis, or renal mass. No radiation. MBS item 55310.

Available CT urogram (multiphasic) Gold standard for upper tract urothelial evaluation. Non-contrast → nephrographic → excretory phases. MBS item 56800 series.

Specialist Flexible cystoscopy Mandatory for visible haematuria >40 years. Performed under local anaesthesia. Referral to urologist required.

Specialist Kidney biopsy Indicated for persistent proteinuria >0.5 g/day with haematuria, declining eGFR, or suspected glomerulonephritis. Performed under ultrasound guidance. Nephrology referral.

Bladder Cancer

Bladder cancer is the 9th most common cancer in Australia, with approximately 3,100 new diagnoses and 1,000 deaths annually. Urothelial (transitional cell) carcinoma accounts for >90% of cases. Smoking is responsible for approximately 50% of bladder cancers in Australia; other risk factors include occupational exposure to aromatic amines (rubber, dye, leather industries), cyclophosphamide, pelvic radiation, chronic schistosomiasis (relevant in migrant populations from endemic regions), and aristolochic acid.

Classification & Staging

Stage	Description	Management
Non-muscle-invasive (NMIBC) — Ta, T1, Tis	Confined to mucosa (Ta) or lamina propria (T1); carcinoma in situ (Tis)	TURBT ± intravesical BCG. Surveillance cystoscopy every 3–12 months.
Muscle-invasive (MIBC) — T2–T4	Invading muscularis propria or beyond	Neoadjuvant chemotherapy + radical cystectomy or trimodal therapy (TURBT + chemoradiation)
Metastatic — M1	Distant metastases (lung, liver, bone)	Platinum-based chemotherapy (gemcitabine + cisplatin) ± immunotherapy (pembrolizumab, avelumab)

Clinical Presentation

Painless visible haematuria — the hallmark presentation (80–90% of cases)
Irritative urinary symptoms (frequency, urgency, dysuria) — especially with carcinoma in situ
Clot retention or obstructive symptoms if tumour at bladder neck
Flank pain if ureteric orifice obstruction causes hydronephrosis
Constitutional symptoms (weight loss, fatigue) in advanced disease

Investigation

CT Urogram

Multiphasic CT to evaluate upper tracts and staging. Characteristic findings: enhancing intraluminal filling defect, hydronephrosis, or soft-tissue mass.

Cystoscopy + TURBT

Cystoscopy identifies the tumour; transurethral resection of bladder tumour (TURBT) provides histological diagnosis, staging (muscle present in specimen is essential), and initial treatment for NMIBC.

Urine Cytology

High specificity for high-grade tumours and carcinoma in situ, but low sensitivity for low-grade disease. Use as adjunct, not screening.

Staging CT (Chest/Abdomen/Pelvis)

For muscle-invasive disease: CT chest and bone scan if clinically indicated. PET-CT may be considered for equivocal metastatic disease.

Management

Non-muscle-invasive bladder cancer (NMIBC): Complete TURBT followed by a single immediate post-operative intravesical mitomycin C instillation (within 24 hours). Intermediate- and high-risk NMIBC requires adjuvant intravesical BCG (bacillus Calmette–Guérin) — induction: 6 weekly instillations, followed by maintenance therapy for up to 3 years. Surveillance cystoscopy is performed at 3 months, then 6-monthly for 2 years, then annually for at least 5 years.

Muscle-invasive bladder cancer (MIBC): The standard of care in Australia is neoadjuvant cisplatin-based combination chemotherapy (e.g., gemcitabine + cisplatin, 4 cycles) followed by radical cystectomy with pelvic lymph node dissection. Trimodal therapy (maximal TURBT + concurrent chemoradiation) is an alternative for patients unfit for or declining surgery. Pembrolizumab (MBS/RPBS) or avelumab maintenance is available for locally advanced or metastatic urothelial carcinoma.

⚠️

Key Australian consideration: BCG supply has been intermittently disrupted globally. The Therapeutic Goods Administration (TGA) manages allocation through Australian hospitals. Oncology and urology units should use intravesical alternatives (mitomycin C, gemcitabine, or sequential gemcitabine/docetaxel) when BCG is unavailable.

Nephritic Syndrome

Nephritic syndrome is a clinical constellation resulting from glomerular inflammation. It is characterised by haematuria (typically with dysmorphic RBCs and RBC casts), hypertension, oliguria, fluid retention / oedema, and acute kidney injury (rising creatinine). Proteinuria is present but typically subnephrotic (<3.5 g/day), distinguishing it from nephrotic syndrome.

Nephritic Syndrome vs Nephrotic Syndrome

Feature	Nephritic Syndrome	Nephrotic Syndrome
Haematuria	Prominent — dysmorphic RBCs, RBC casts	Minimal or absent
Proteinuria	Subnephrotic (<3.5 g/day)	Nephrotic range (>3.5 g/day)
Blood pressure	Hypertension common	Variable
Oedema	Mild–moderate (fluid retention)	Severe generalised (hypoalbuminaemia)
Renal function	AKI — rising creatinine, oliguria	Often preserved initially
Serum albumin	Mildly reduced or normal	Markedly reduced (<25 g/L)
Common causes	IgA nephropathy, PSGN, lupus nephritis, ANCA vasculitis, anti-GBM disease	Minimal change disease, FSGS, membranous nephropathy, diabetic nephropathy

Causes of Nephritic Syndrome

Category	Condition	Key Investigations
Primary GN	IgA nephropathy	Serum IgA (may be elevated), C3 normal or mildly low; biopsy: mesangial IgA deposits
Post-infectious	Post-streptococcal GN	Low C3 (usually <50% normal), elevated ASOT/anti-DNase B; biopsy: subepithelial humps
Autoimmune	Lupus nephritis (class III/IV)	ANA +ve, anti-dsDNA +ve, low C3 and C4, biopsy: full-house IF
Vasculitis	ANCA-associated vasculitis (GPA, MPA)	MPO-ANCA or PR3-ANCA +ve, crescentic GN on biopsy
Anti-GBM	Anti-GBM disease (Goodpasture's)	Anti-GBM antibodies +ve, linear IgG on IF; may have pulmonary haemorrhage
Other	MPGN, cryoglobulinaemic GN, infective endocarditis	Cryoglobulins, blood cultures, hepatitis C serology

Rapidly Progressive Glomerulonephritis (RPGN)

🚨

Medical emergency: RPGN is defined as a >50% decline in eGFR over days to weeks with active urine sediment. Causes include ANCA vasculitis, anti-GBM disease, and IgA nephropathy with crescents. Urgent nephrology referral is required — delay in treatment leads to irreversible renal damage. Pulse IV methylprednisolone (500–1000 mg daily for 3 days) is typically initiated while awaiting biopsy results. Plasma exchange may be indicated for anti-GBM disease or severe ANCA vasculitis with pulmonary haemorrhage.

Supportive Management of Nephritic Syndrome

Blood pressure control: Target <130/80 mmHg. ACE inhibitors (ramipril 2.5–10 mg daily) or ARBs (irbesartan 150–300 mg daily) are first-line — provide renoprotection and reduce proteinuria.
Fluid management: Restrict sodium (<2 g/day), restrict fluid intake if oliguric. Diuretics (furosemide 20–80 mg PO/IV) for volume overload.
Hyperkalaemia: Monitor closely. Dietary potassium restriction. Calcium gluconate 10% 10 mL IV for acute stabilisation. Insulin–dextrose infusion. Sodium polystyrene sulfonate (Resonium A) or patiromer for ongoing management.
Dialysis: Initiate for refractory hyperkalaemia, severe metabolic acidosis, fluid overload unresponsive to diuretics, or uraemic symptoms (encephalopathy, pericarditis).
Infection screening: Treat any underlying infection. Screen for endocarditis, hepatitis B/C, and HIV where indicated.

IgA Nephropathy

IgA nephropathy (IgAN; Berger disease) is the most common primary glomerulonephritis worldwide and in Australia, accounting for 25–40% of primary GN diagnoses. It is characterised by mesangial deposition of galactose-deficient IgA1 (Gd-IgA1) with subsequent immune complex formation and complement activation, leading to mesangial proliferation and variable degrees of glomerular injury.

Clinical Presentation

Episodic macroscopic haematuria (synpharyngitic haematuria) — the hallmark presentation in children and young adults. Haematuria coincides with or occurs within 1–2 days of an upper respiratory tract infection or gastroenteritis. This distinguishes it from PSGN, where haematuria occurs 1–3 weeks after infection.
Persistent microscopic haematuria ± subnephrotic proteinuria — the most common presentation in adults detected incidentally.
Nephrotic syndrome — less common; suggests significant glomerular injury or superimposed pathology.
RPGN — rare but severe; crescentic IgA nephropathy has a poor prognosis without aggressive immunosuppression.
AKI — can occur during episodes of macroscopic haematuria (often self-limiting, resolves over days).

Diagnosis

Definitive diagnosis requires kidney biopsy showing mesangial IgA deposits on immunofluorescence (≥2+ intensity), often with co-deposition of C3 and IgG/IgM. Light microscopy shows mesangial hypercellularity (variable). Electron microscopy reveals mesangial electron-dense deposits.

ℹ️

Serum IgA level: An elevated serum IgA is supportive but not diagnostic — it is elevated in only 30–50% of IgAN patients and has poor sensitivity and specificity. It should not be used to rule in or rule out the diagnosis.

Risk Stratification (Oxford MEST-C Score)

Score	Parameter	Description	Prognostic Implication
M	Mesangial hypercellularity	M0 (<50%) vs M1 (≥50%)	M1 associated with worse renal outcome
E	Endocapillary hypercellularity	E0 absent vs E1 present	E1 predicts better response to immunosuppression
S	Segmental sclerosis	S0 absent vs S1 present	S1 independent predictor of progression
T	Tubular atrophy/interstitial fibrosis	T0 (<25%), T1 (25–50%), T2 (>50%)	T1/T2 — strongest predictor of ESKD
C	Crescents	C0 absent, C1 (<25%), C2 (≥25%)	C2 associated with RPGN and aggressive disease

Management

Supportive therapy (all patients):

ACE inhibitor or ARB — maximally tolerated dose for proteinuria ≥0.5 g/day. Target BP <130/80 mmHg.
Sodium restriction (<2 g/day), smoking cessation, weight management.
Monitor: eGFR, urine ACR, blood pressure at least every 3–6 months.
SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) — recommended per KDIGO 2021 and recent Australian PBS listings for CKD, independent of diabetes status, for renoprotection in patients with eGFR ≥20 mL/min and proteinuria.

Immunosuppressive therapy (selected patients):

⚠️

When to consider immunosuppression: After ≥90 days of maximal supportive therapy (ACEi/ARB + SGLT2i) with persistent proteinuria >1 g/day and declining eGFR. IgAN prognosis is driven primarily by proteinuria and eGFR trajectory — treat the proteinuria first, then escalate if inadequate response.

First-line immunosuppression: Systemic corticosteroids — prednisolone 0.5–1 mg/kg/day (max 40–60 mg) for 2 months, then tapered over 4–6 months. Consider reduced-dose regimen (TESTING protocol: methylprednisolone 0.4 mg/kg/day for 2 months, taper over 4–6 months) to minimise side effects.
Alternative: Mycophenolate mofetil (CellCept®) 500–1000 mg PO BD — evidence is mixed but may be considered in patients with steroid intolerance or as steroid-sparing agent.
Crescentic IgA nephropathy (RPGN): Treat as for ANCA vasculitis — pulse IV methylprednisolone followed by oral prednisolone + cyclophosphamide (cyclophosphamide 2.5 mg/kg/day PO or IV pulse per Euro-Lupus protocol).
Novel therapies: Nefecon (Tarsier® / Budesonide delayed-release — targeting mucosal IgA production) — approved by TGA and listed on PBS as Authority Required for primary IgA nephropathy with proteinuria ≥1 g/day despite optimised supportive care. Sibeprenlimab — a novel Gd-IgA1-targeting monoclonal antibody under investigation in Phase 3 trials (ORIGIN 3 trial).

💊

Dapagliflozin

Forxiga® · SGLT2 inhibitor

Adult dose 10 mg PO once daily (CKD indication)

Renal adjustment Initiate if eGFR ≥20 mL/min; may continue below 20 for CKD benefit per KDIGO 2024

PBS status ✔ PBS Authority Required (CKD with eGFR 25–75, ACR ≥30)

💊

Nefecon (Budesonide delayed-release)

Tarsier® · Targeted-release corticosteroid

Adult dose 16 mg PO once daily in the morning (4 × 4 mg capsules) for 9 months

Key note Targeted release to distal ileum — suppresses mucosal Gd-IgA1 production. Reduced systemic corticosteroid effects.

PBS status ✔ PBS Authority Required (primary IgAN with proteinuria ≥1 g/day despite optimised RAASi)

Prognosis

Approximately 25–30% of patients with IgAN progress to ESKD within 20 years. Prognostic factors for progression include persistent proteinuria >1 g/day, hypertension at presentation, declining eGFR, and severe histological changes (high MEST-C score with tubulointerstitial fibrosis). Long-term nephrology follow-up is essential for all patients with biopsy-proven IgAN.

Post-Streptococcal Glomerulonephritis (PSGN)

Post-streptococcal glomerulonephritis (PSGN) is an immune-mediated glomerular injury triggered by infection with nephritogenic strains of Streptococcus pyogenes (Group A streptococcus, GAS). While PSGN incidence has declined in high-income countries, it remains a significant health burden in Aboriginal and Torres Strait Islander communities, particularly in the Northern Territory, Western Australia, and Central Australia, where the incidence is among the highest globally (estimated 60–240 per 100,000 children per year in remote Indigenous communities).

Pathophysiology

Nephritogenic GAS strains (predominantly M-types 1, 2, 4, 12, 25, 49, 55, 57, and 60) produce antigens (e.g., nephritis-associated plasmin receptor [NAPlr], streptococcal pyrogenic exotoxin B [SPE B]) that are deposited in the glomerulus. Immune complex formation activates complement (primarily via the alternative pathway, causing low C3), recruiting neutrophils and monocytes, resulting in endocapillary proliferation and a characteristic "lumpy-bumpy" pattern on light microscopy with subepithelial "humps" on electron microscopy.

Clinical Presentation

Classic Presentation (Children)

Antecedent GAS pharyngitis (1–3 weeks prior) or impetigo/pyoderma (3–6 weeks prior)
Acute onset: visible haematuria (smoky/cola-coloured urine)
Oedema (periorbital, dependent) — classically worse in the morning
Hypertension (often severe in children)
Oliguria
May present with hypertensive encephalopathy (headache, seizures, visual disturbance)

Atypical / Adult Presentation

May present as nephritic-nephrotic overlap syndrome
Elderly: may present with AKI and fluid overload without classic history
Rarely: RPGN with crescentic transformation (>50% crescents on biopsy)
Post-streptococcal: may lack clear antecedent history
Dense deposit disease can mimic PSGN — check C3 levels over time (persistent low C3 suggests alternative diagnosis)

Diagnosis

Investigation	Expected Finding	Notes
Urinalysis	Haematuria (dysmorphic RBCs, RBC casts), subnephrotic proteinuria	Active urinary sediment is the hallmark
Serum C3 complement	Low (often <50% of normal)	Returns to normal within 6–8 weeks in PSGN. Persistent low C3 >8 weeks suggests alternative diagnosis (MPGN, lupus nephritis, dense deposit disease).
Serum C4 complement	Normal or mildly low	Markedly low C4 suggests classical pathway activation (lupus, MPGN, cryoglobulinaemia)
ASOT / Anti-DNase B	Elevated (evidence of recent GAS infection)	Anti-DNase B is more sensitive for skin infections. ASOT for pharyngeal infections.
Serum creatinine / eGFR	Elevated (AKI)	Usually self-limiting in children; may be severe in adults
Kidney biopsy	Diffuse endocapillary proliferative GN; subepithelial humps on EM	Not always required if classic presentation with low C3 and positive strep serology. Indicated for atypical course, persistent renal impairment >2–3 weeks, or RPGN features.

Differentiating PSGN from IgA Nephropathy

Feature	PSGN	IgA Nephropathy
Age	Children (3–12 years peak)	Children and young adults (15–35 years peak)
Onset relative to infection	1–3 weeks (pharyngitis) or 3–6 weeks (skin) AFTER infection	Concurrent or within 1–2 days of mucosal infection
C3 complement	Low — normalises by 6–8 weeks	Normal or mildly low
C4 complement	Normal	Normal
ASOT / Anti-DNase B	Elevated	Normal
Serum IgA	Normal	Elevated in 30–50%
Recurrence	Rare (typically one episode)	Common — progressive in 25–30%
Biopsy IF	Granular IgG and C3 ("starry sky")	Mesangial IgA dominant

Management of PSGN

PSGN is primarily a self-limiting disease in children — no specific treatment accelerates recovery. Management is supportive:

Treat underlying GAS infection: Oral phenoxymethylpenicillin (penicillin V) 500 mg PO BD (adults) or 250 mg PO BD (children <25 kg) for 10 days. Alternative: amoxicillin 500 mg TDS (adults) or 25 mg/kg/day in divided doses (children), or intramuscular benzathine penicillin G (Bicillin L-A®) 1.2 MU (adults) or 600,000 units (children <27 kg) as a single dose.
Fluid and sodium restriction: Restrict sodium to <2 g/day; restrict fluid intake to insensible losses + urine output.
Diuretics: Furosemide 1–2 mg/kg IV (max 40 mg) for acute pulmonary oedema or severe oedema. Avoid aggressive diuresis — risk of prerenal AKI.
Antihypertensives: Nifedipine (short-acting sublingual for hypertensive emergency) or amlodipine for ongoing control. ACE inhibitors may be used cautiously once renal function is improving.
Dialysis: Required in <1% of children; may be necessary in adults with severe AKI, refractory hyperkalaemia, or pulmonary oedema.
Corticosteroids/immunosuppression: Not indicated for typical PSGN. Consider in crescentic PSGN (RPGN) — treat as per RPGN protocol.
Prophylaxis: Treat household contacts of GAS to prevent further nephritogenic strain circulation (particularly in high-prevalence communities).

ℹ️

Prognosis: In children, >95% recover completely with supportive care. In adults, prognosis is more guarded — up to 20–40% may have persistent proteinuria or reduced renal function. Elderly patients with crescentic disease have the worst prognosis, with mortality rates of 20–30%. Long-term follow-up (6–12 months minimum) with repeat urinalysis, blood pressure, and eGFR monitoring is recommended for all patients.

Public Health: GAS Control in Australian Communities

In remote Aboriginal and Torres Strait Islander communities, GAS pharyngitis and impetigo are endemic, contributing to extremely high rates of PSGN and acute rheumatic fever (ARF). The Australian Department of Health and Aged Care recommends a combination of primary prevention (improved housing, hygiene, and access to healthcare), secondary prophylaxis (regular benzathine penicillin injections for ARF/RHD), and community-based sore throat and skin sore surveillance programs.

Investigations: Australian Availability & MBS Items

Essential MSU — microscopy, culture, sensitivity Available through all Australian pathology providers (Sonic, Healius, PathWest in WA, QML in QLD, SA Pathology). MBS item 69315 (culture) and 69300 (microscopy).

Essential Urine ACR First-void morning specimen preferred. MBS item 66892. Available in all labs; point-of-care devices available in some remote clinics.

Essential Serum creatinine, eGFR, electrolytes MBS item 66503. eGFR calculated using CKD-EPI equation. Standard in all Australian pathology services.

Essential FBC, CRP, ESR Assess for infection, inflammation, anaemia of chronic disease. MBS item 65070 (FBC), 65060 (CRP).

Available Serum complement (C3, C4) MBS item 65094. Available in major pathology networks. Essential for nephritic syndrome workup — low C3 + normal C4 = PSGN, IgAN, MPGN; low C3 + low C4 = lupus, MPGN, cryoglobulinaemia.

Available ASOT / Anti-DNase B MBS item 65094. ASOT more sensitive for pharyngitis; Anti-DNase B more sensitive for skin infections. Both available through major labs. Point-of-care rapid strep tests available for pharyngitis (sensitivity ~70–90%).

Available ANCA (MPO, PR3), Anti-GBM, ANA, anti-dsDNA MBS item 65094. Autoimmune serology panels available in all major labs. Refer to rheumatology/nephrology for positive results.

Available Renal tract ultrasound MBS item 55310. Non-invasive, no radiation. Available in metropolitan and most regional centres. First-line imaging for renal calculi, hydronephrosis, renal size asymmetry.

Available CT urogram (multiphasic) MBS item 56800 series. Requires IV contrast (check eGFR). Available in metropolitan and most regional hospitals. Gold standard for upper tract urothelial malignancy.

Specialist Flexible cystoscopy Performed by urologist. Outpatient procedure under local anaesthesia. Requires referral.

Specialist Kidney biopsy Percutaneous under ultrasound guidance. Performed by nephrologist in hospital setting. Requires coagulation check and cross-match. Nephrology referral essential.

Specialist Urine red cell morphology Phase-contrast microscopy to distinguish dysmorphic (glomerular) from isomorphic (urological) RBCs. Available in select pathology labs; may require specialist request.

Special Populations

🤰

Pregnancy

UTI in pregnancy: Treat all bacteriuria (even asymptomatic) — increased risk of pyelonephritis and preterm labour. Nitrofurantoin 100 mg BD for 5 days (avoid at term — risk of neonatal haemolysis). Cefalexin 500 mg QID for 5 days is a safe alternative. Avoid trimethoprim in first trimester (folate antagonist). Fluoroquinolones contraindicated.

Haematuria: Physiological haematuria can occur in pregnancy due to ureteric dilation. However, pathological causes must be excluded. MRI without contrast is the preferred imaging modality (avoids radiation). CT urogram contraindicated due to fetal radiation exposure.

Glomerulonephritis in pregnancy: Requires nephrology and obstetric co-management. Lupus nephritis may flare in pregnancy. IgA nephropathy generally does not worsen but requires close monitoring. Prednisolone and azathioprine are relatively safe; mycophenolate is teratogenic (Category D — must be ceased at least 6 weeks before conception).

Blood pressure targets: ≤135/85 mmHg in pregnancy. Labetalol, nifedipine, and methyldopa are first-line. ACE inhibitors and ARBs are contraindicated (teratogenic — fetopathy with oligohydramnios, renal dysplasia).

👶

Paediatrics

UTI in children: Common — up to 8% of febrile children <2 years have UTI. Collect specimen by clean-catch (preferred) or catheter. Bag specimens are acceptable for screening but not culture. Treat empirically with trimethoprim (if local resistance <20%) or cefalexin pending culture. All children with first febrile UTI should have renal tract ultrasound to assess for structural abnormalities.

PSGN: Most common cause of acute nephritis in Australian children aged 3–12 years. Self-limiting in >95%. Monitor closely for complications: hypertensive encephalopathy, pulmonary oedema, AKI requiring dialysis.

IgA nephropathy: Most common GN in children and adolescents. Presentation with recurrent macroscopic haematuria is more common in children than adults. Nephrology referral for all biopsy-confirmed cases.

Bladder cancer: Extremely rare in children. Transitional cell carcinoma is essentially not seen in the paediatric population. Rhabdomyosarcoma of the bladder is the primary malignant consideration — presents with haematuria, obstruction, and a pelvic mass. Urgent paediatric oncology referral.

Dosing considerations: Nitrofurantoin contraindicated <3 months. Trimethoprim: 4 mg/kg (max 300 mg). Cefalexin: 25–50 mg/kg/day in divided doses. Doxycycline contraindicated <8 years (dental staining).

👴

Elderly

Asymptomatic bacteriuria: Very common (up to 20–50% of elderly women in residential care). Do NOT treat unless pregnant or pre-urological procedure. Unnecessary antibiotic use drives resistance and C. difficile infection.

Bladder cancer: Median age at diagnosis is 73 years. The differential for haematuria broadens with age — BPH, urolithiasis, anticoagulant-related bleeding, and malignancy all become more prevalent.

PSGN in the elderly: Rare but carries significant morbidity and mortality. May present atypically with AKI, fluid overload, and confusion. Crescentic disease is more common — early nephrology referral is essential.

Renal function: eGFR declines with age (~1 mL/min/year after age 40). Adjust renally cleared medications. Avoid nephrotoxic agents where possible. Renal ultrasound is preferred over CT to avoid contrast nephrotoxicity in CKD patients.

🫘

Renal Impairment

Nitrofurantoin: Contraindicated if eGFR <30 mL/min — ineffective (insufficient urinary concentration) and risk of peripheral neuropathy.

Trimethoprim: Reduce dose if eGFR <30 mL/min; avoid if eGFR <15 mL/min. May cause transient rise in serum creatinine by inhibiting tubular secretion.

Contrast nephropathy: Pre-hydration with IV normal saline (1 mL/kg/hr for 6–12 hours pre- and post-contrast) for patients with eGFR <30 mL/min receiving iodinated contrast. Use low-osmolar or iso-osmolar contrast agents. Metformin should be withheld for 48 hours post-contrast if eGFR <30.

Immunosuppression dose adjustment: Cyclophosphamide requires dose reduction in severe renal impairment. Mycophenolate does not require dose adjustment but monitor for leucopenia.

🫁

Hepatic Impairment

Nitrofurantoin: Use with caution in hepatic impairment — risk of hepatotoxicity. Monitor LFTs if prolonged use.

Immunosuppression: Mycophenolate is hepatically metabolised — no specific dose adjustment required but monitor closely. Cyclophosphamide may require dose reduction in severe hepatic impairment. Corticosteroids may exacerbate hepatic encephalopathy in cirrhosis.

Hepatitis-associated GN: Hepatitis B and C are important causes of glomerulonephritis in Australia. Hepatitis B-associated membranous nephropathy and MPGN require antiviral therapy (entecavir, tenofovir) as primary treatment. Hepatitis C-associated cryoglobulinaemic GN requires direct-acting antiviral (DAA) therapy.

🛡️

Immunocompromised

UTI in immunocompromised patients: Consider all UTIs as complicated. Broader empirical antibiotics may be needed (e.g., ceftriaxone 1 g IV daily or piperacillin-tazobactam 4.5 g IV TDS for suspected resistant organisms). Always obtain cultures before initiating treatment.

Fungal UTI: Candida UTI is increasingly common in immunocompromised, diabetic, and catheterised patients. Fluconazole 200 mg PO/IV daily for 14 days is first-line for symptomatic candiduria. Amphotericin B bladder irrigation for refractory cases.

Drug-induced GN: Immune checkpoint inhibitors (pembrolizumab, nivolumab) can cause acute interstitial nephritis and immune-mediated GN. Cyclophosphamide can cause haemorrhagic cystitis (use mesna for prevention).

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Kidney disease disproportionately affects Aboriginal and Torres Strait Islander Australians. The burden of glomerulonephritis — particularly PSGN and IgA nephropathy — is driven by a complex interplay of social determinants of health, geographic isolation, limited healthcare access, and high rates of streptococcal skin and throat infections. These factors demand a culturally safe, community-centred approach to prevention, diagnosis, and management.

Key Disparities

Aboriginal and Torres Strait Islander Australians are 3.8 times more likely to be hospitalised with CKD and have ESKD rates 6–8 times higher than non-Indigenous Australians (AIHW 2023).
PSGN incidence in remote Northern Territory Indigenous children is estimated at 60–240 per 100,000 per year — among the highest globally.
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD), caused by the same GAS organism, are virtually absent in non-Indigenous Australians but remain endemic in remote Indigenous communities — further highlighting the GAS disease burden.
Bladder cancer incidence is higher in Aboriginal and Torres Strait Islander populations, with later-stage presentation and poorer outcomes, partly due to delayed access to specialist services.

Barriers to Optimal Care

Geographic isolation

Many remote communities are >500 km from the nearest nephrology or urology service. Retrieval for acute presentations (e.g., RPGN, hypertensive emergency) may take hours. Royal Flying Doctor Service (RFDS) provides emergency retrieval but capacity is limited.

Specialist access

Nephrology and urology telehealth services are available through NT Renal Service, WA Country Health Service, and state-based specialist outreach programs. Kidney biopsy requires transfer to a tertiary centre (e.g., Royal Darwin Hospital, Alice Springs Hospital, Royal Perth Hospital).

Point-of-care testing

POC creatinine, eGFR, ACR, and urine dipstick analysers are available in many remote Aboriginal Community Controlled Health Organisations (ACCHOs). The eGFR equation should be used with caution — there is debate about the accuracy of creatinine-based eGFR in Indigenous populations (some centres use cystatin C–based equations).

Cultural safety

Engage Aboriginal Health Workers and Aboriginal Liaison Officers as essential members of the care team. Respect cultural protocols around gender, sorry business (bereavement), and traditional healing. Use plain language and visual aids. Ensure interpreter services are available for speakers of Aboriginal English or traditional languages.

Medication access

Remote communities may lack pharmacies; medicines are supplied through Remote Area Aboriginal Health Services (RAAHS) or Section 100 (S100) arrangements. Long-acting penicillin (benzathine penicillin G) for ARF prophylaxis is a critical supply chain priority. PBS Close the Gap CTG scripts provide subsidised medicines for Indigenous Australians with chronic disease.

Social determinants

Overcrowded housing, limited access to clean water and sanitation in some communities, food insecurity (limited access to fresh food at affordable prices), and socioeconomic disadvantage all contribute to high infection rates and chronic disease burden.

Recommended Strategies

GAS control programs: Support community-based sore throat and skin sore surveillance and treatment programs in high-prevalence communities (e.g., Deadly Ears, NT Rheumatic Heart Disease Program).
Secondary prophylaxis: For patients with ARF/RHD, regular benzathine penicillin G injections (every 21–28 days) also reduce recurrent GAS exposure and risk of PSGN.
Kidney Health Australia KHA-CARI guidelines: Ensure screening for CKD in at-risk Indigenous adults (urine ACR, eGFR, BP) as part of annual Aboriginal and Torres Strait Islander Health Checks (MBS item 715).
ACCHO-led care: Support Aboriginal Community Controlled Health Organisations to deliver chronic disease management, with nephrology and urology input via telehealth and outreach clinics.
Dialysis in community: Satellite dialysis units in regional centres (e.g., Alice Springs, Broome, Katherine, Mt Isa) reduce the need for patients to relocate to metropolitan centres, supporting family and cultural connection.

💚

Key resource: The Kidney Health Australia — Caring for Australasians with Renal Impairment (KHA-CARI) guidelines and the RHDAustralia guidelines for ARF/RHD provide evidence-based recommendations specific to the Australian context, including Aboriginal and Torres Strait Islander health considerations. Access at kidney.org.au and rhdaustralia.org.au.

📚 References

1. Kidney Health Australia. Caring for Australasians with Renal Impairment (KHA-CARI) Guidelines. Melbourne: Kidney Health Australia; 2024. Available from: kidney.org.au.
2. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease: Australian facts. AIHW Cat. No. CDK 12. Canberra: AIHW; 2023.
3. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100(4S):S1–S276.
4. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–S314.
5. RHDAustralia (Rheumatic Heart Disease Australia). 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
6. National Health and Medical Research Council (NHMRC). Australian guidelines for the prevention and control of infection in healthcare. Canberra: NHMRC; 2019 (updated 2024).
7. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
8. Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2019;95(6):1224–1236.
9. Barratt J, Lafayette R, Zhang H, et al. Nefecon in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10417):2077–2090.
10. Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy (TESTING): a randomized clinical trial. JAMA. 2022;327(19):1888–1898.
11. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020;383(15):1436–1446.
12. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 9th ed. Melbourne: RACGP; 2016 (updated 2024).
13. Australasian Society for Infectious Diseases (ASID). Guidelines for the management of asymptomatic bacteriuria in adults. Melbourne: ASID; 2022.
14. Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control on chronic kidney disease progression in type 2 diabetes. Kidney International. 2020;98(5):1206–1216.
15. > Cancer Council Australia. Clinical practice guidelines for the management of bladder cancer. Sydney: Cancer Council Australia; 2023. Available from: wiki.cancer.org.au.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).